Patents by Inventor Sandra Ann Filla

Sandra Ann Filla has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Excitatory amino acid receptor antagonists
    Patent number: 6855725
    Abstract: The present invention provides compounds of Formula I or Formula II, or the pharmaceutically acceptable salts or prodrugs thereof, pharmaceutical compositions comprising compounds or Formula I or Formula II, and methods for treating neurological disorders and neurodegenerative diseases, particularly migraine.
    Type: Grant
    Filed: December 20, 2001
    Date of Patent: February 15, 2005
    Assignee: Eli Lilly and Company
    Inventors: Thomas John Bleisch, Sandra Ann Filla, Paul Leslie Ornstein
  • Selective iGluR5 receptor antagonists
    Publication number: 20040192722
    Abstract: The present invention provides a method of treating or preventing migraine comprising administering to a patient in need thereof an effective amount of a selective iGluR5 receptor antagonist. The present invention further provides novel compounds functional as selective iGluR5 receptor antagonists as well as compositions and formulations comprising said selective iGluR5 receptor antagonists.
    Type: Application
    Filed: April 9, 2004
    Publication date: September 30, 2004
    Inventors: Sandra Ann Filla, Paul Leslie Ornstein
  • Selective iGluR5 receptor antagonists for the treatment of neurological disorders
    Patent number: 6759418
    Abstract: The present invention provides a method of treating or preventing migraine comprising administering to a patient in need thereof an effective amount of a selective iGluR5 receptor antagonist. The present invention further provides novel compounds functional as selective iGluR4 receptor antagonists as well as compositions and formulations comprising said selective iGluR5 rec antagonists.
    Type: Grant
    Filed: March 6, 2003
    Date of Patent: July 6, 2004
    Assignee: Eli Lilly and Company
    Inventors: Sandra Ann Filla, Paul Leslie Ornstein
  • Benzenesulfonic acid indol-5-yl esters as antagonists of the 5-ht6 receptor
    Publication number: 20040102481
    Abstract: The present invention relates to compounds of formula I: which are antagonists of 5-HT6 receptor.
    Type: Application
    Filed: July 22, 2003
    Publication date: May 27, 2004
    Inventors: Sandra Ann Filla, Michael Edward Flaugh, James Ronald Gillig, Lawrence Joseph Heinz, Joseph Herman Krushinski, Bin Liu, Marta Maria Pineiro-Nunez, John Mehnert Schaus, John Stanley Ward
  • Excitatory amino acid receptor antagonists
    Publication number: 20040063749
    Abstract: The present invention provides compounds of Formula I or Formula II, or the pharmaceutically acceptable salts or prodrugs thereof, pharmaceutical compositions comprising compounds or Formula I or Formula II, and methods for treating neurological disorders and neurodegenerative diseases, particularly migraine.
    Type: Application
    Filed: June 25, 2003
    Publication date: April 1, 2004
    Inventors: Thomas John Bleisch, Sandra Ann Filla, Paul Leslie Ornstein
  • 5-HT1F agonists
    Patent number: 6696439
    Abstract: The present invention relates to substituted furo[3,2-b]pyridine compounds of formula I: or a pharmaceutical acid addition salt thereof; where; R is E—D is C═CH or CH—CH2; R1 is hydrogen or C1-C4 alkyl; R2 is hydrogen, halo, hydroxy, —NR3R4, —SR3, —C(O)R3, —C(O)MR3R4, —NR3SO2R5, —NHC(Q)NR3R4, —NHC(O)OR3, or —NR3C(O)R5; R3, R4, and R5 are independently hydrogen, C1-C4 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, or —(CH2)naryl; or R3 and R4 combine, together with the nitrogen to which they are attached, form a pyrrolidine, piperidine, piperazine, 4-substituted piperazine, morpholine, or thiomorpholine ring; n is 0, 1, 2, 3, 4, 5, or 6; and Q is O or S. The present invention further relates to pharmaceutical.
    Type: Grant
    Filed: August 1, 2001
    Date of Patent: February 24, 2004
    Assignee: Eli Lilly and Company
    Inventors: Sandra Ann Filla, Brian Michael Mathes
  • Selective iGluR5 receptor antagonists for the treatment of neurological disorders
    Publication number: 20030199546
    Abstract: The present invention provides a method of treating or preventing migraine comprising administering to a patient in need thereof an effective amount of a selective iGluR5 receptor antagonist. The present mvention further provides novel compounds functional as selective iGluR5 receptor antagonists as well as compositions and s cspng said selective iGluR5 receptor antagonists.
    Type: Application
    Filed: March 6, 2003
    Publication date: October 23, 2003
    Inventors: Sandra Ann Filla, Paul Leslie Ornstein
  • Selective iGluR5 receptor antagonists for the treatment of migraine
    Patent number: 6566370
    Abstract: The present invention provides a method of treating or preventing migraine comprising administering to a patient in need thereof an effective amount of a selective iGluR5 receptor antagonist. The present invention further provides novel compounds functional as selective iGluR5 receptor antagonists as well as compositions and formulations comprising said selective iGluR5 receptor antagonists.
    Type: Grant
    Filed: December 11, 2001
    Date of Patent: May 20, 2003
    Assignee: Eli Lilly and Company
    Inventors: David Bleakman, Sandra Ann Filla, Kirk Willis Johnson, Paul Leslie Ornstein
  • 5-HT1F agonists
    Patent number: 6358972
    Abstract: The present invention relates to a compound of formula (I): or a pharmaceutical acid addition salt thereof; which is useful for activating 5-HT1f receptors and inhibiting protein extravasation in a mammal.
    Type: Grant
    Filed: December 5, 2000
    Date of Patent: March 19, 2002
    Assignee: Eli Lilly and Company
    Inventors: Sandra Ann Filla, Daniel James Koch, Brian Michael Mathes, Vincent Patrick Rocco
  • 5-HT.sub.1F agonists intermediates
    Patent number: 5998622
    Abstract: This invention provides 5-HT.sub.1F agonists of Formula I; ##STR1## where A-B, X, and R are as defined in the specification. The invention also encompasses pharmaceutical formulations employing compounds of Formula I as well as methods of treating conditions associated with 5-HT.sub.1F activation employing these compounds or compositions. The invention also provides intermediates useful for the preparation of the compounds of Formula I.
    Type: Grant
    Filed: July 9, 1998
    Date of Patent: December 7, 1999
    Assignee: Eli Lilly and Company
    Inventors: Sandra Ann Filla, Kirk W. Johnson, Lee A. Phebus, John Mehnert Schaus
  • Nitropyridine compound
    Patent number: 5919936
    Abstract: This invention provides 5-HT.sub.1F agonists of Formula I: ##STR1## where A-B, X, and R are as defined in the specification. The invention also encompasses pharmaceutical formulations employing compounds of Formula I as well as methods of treating conditions associated with 5-HT.sub.1F activation employing these compounds or compositions. The invention also provides intermediates useful for the preparation of the compounds of Formula I.
    Type: Grant
    Filed: July 9, 1998
    Date of Patent: July 6, 1999
    Assignee: Eli Lilly and Company
    Inventors: Sandra Ann Filla, Kirk W. Johnson, Lee A. Phebus, John Mehnert Schaus
  • 5-HT.sub.1F agonists
    Patent number: 5817671
    Abstract: This invention provides 5-HT.sub.1F agonists of Formula I: ##STR1## where A--B, X, and R are as defined in the specification. The invention also encompasses pharmaceutical formulations employing compounds of Formula I as well as methods of treating conditions associated with 5-HT.sub.1F activation employing these compounds or compositions. The invention also provides intermediates useful for the preparation of the compounds of Formula I.
    Type: Grant
    Filed: November 14, 1997
    Date of Patent: October 6, 1998
    Assignee: Eli Lilly and Company
    Inventors: Sandra Ann Filla, Kirk W. Johnson, Lee A. Phebus, John Mehnert Schaus